Renal denervation value framework prioritizes efficacy and safety for Chinese hospital procurement
This narrative review describes the development of a comprehensive value assessment framework for renal denervation (RDN) therapy in Chinese hospitals. The framework was constructed using a multi-criteria decision analysis approach, with criteria weights determined by expert input. At the first level, efficacy received the highest weight (23.26%), followed by safety (21.83%), qualification and suitability (16.84%), patient value (15.18%), innovation (10.65%), management value (6.22%), and cost (6.01%). The authors intend this framework to support procurement reviews and decisions for RDN devices in Chinese hospitals.
The review does not report any primary clinical data, sample size, or comparator. It is a methodological paper outlining a decision tool rather than a systematic synthesis of clinical evidence. The framework's weights reflect expert opinion and may not generalize to other settings. No limitations are explicitly acknowledged by the authors.
Clinicians should interpret this framework as a structured approach to evaluating RDN devices for hospital formularies, but its practical utility depends on local validation and integration with clinical evidence. The framework does not replace direct evidence on RDN efficacy or safety in hypertensive patients.